The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma
Open accessAbstract
Aberrant vascularization is a hallmark of cancer progression and treatment resistance. Here, we have shown that endothelial cell (EC) plasticity drives aberrant vascularization and chemoresistance in glioblastoma multiforme (GBM). By utilizing human patient specimens, as well as allograft and genetic murine GBM models, we revealed that a robust endothelial plasticity in GBM allows acquisition of fibroblast transformation (also known as endothelial mesenchymal transition [Endo-MT]), which is characterized by EC expression of fibroblast markers, and determined that a prominent population of GBM-associated fibroblast-like cells have EC origin. Tumor ECs acquired the mesenchymal gene signature without the loss of EC functions, leading to enhanced cell proliferation and migration, as well as vessel permeability. Furthermore, we identified a c-Met/ETS-1/matrix metalloproteinase-14 (MMP-14) axis that controls VE-cadherin degradation, Endo-MT, and vascular abnormality. Pharmacological c-Met inhibition induced vessel normalization in patient tumor-derived ECs. Finally, EC-specific KO of Met inhibited vascular transformation, normalized blood vessels, and reduced intratumoral hypoxia, culminating in suppressed tumor growth and prolonged survival in GBM-bearing mice after temozolomide treatment. Together, these findings illustrate a mechanism that controls aberrant tumor vascularization and suggest that targeting Endo-MT may offer selective and efficient strategies for antivascular and vessel normalization therapies in GBM, and possibly other malignant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Of note, fibroblast-like endothelial cells within the tumour stroma of glioblastoma attenuate the efficacy of TMZ treatment and genetic loss of the hepatocyte growth factor receptor c-Met in endothelial cells synergised with TMZ treatment in a mouse model,156”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [156]
In the citing paper
“suggesting that pharmacologic c-Met inhibition might synergise with TMZ treatment and subsequent ICB in CRC.”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A. K., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,251
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V. E., Traverso, G., Romans, K. E., Montgomery, E. A., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,859
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Cited by
Sorted by citations
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 571
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
Hu, H., Mu, Q., Bao, Z., Chen, Y., Liu, Y., Chen, J., Wang, K., Wang, Z., Nam, Y., Jiang, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.038 · Cited by 345
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J., Bauchet, L., Brisson, L., Cartron, P., Castel, H., Chevet, É., Chneiweiss, H., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 326
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 313
Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 293
Self-citation
Metadata
- Authors
- Huang, M., Liu, T., Ma, P., Mitteer, R. A., Zhang, Z., Kim, H. J., Yeo, E., Zhang, D., Cai, P., Li, C., Zhang, L., Zhao, B., Roccograndi, L., O’Rourke, D. M., Dahmane, N., Gong, Y., Koumenis, C., & Fan, Y.
- Affiliations
- University of Pennsylvania (US)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Shanghai University (CN)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-04-04
- Volume
- 126
- Issue
- 5
- Pages
- 1801-1814
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4855929
- OpenAlex
- W2315035682
- Cited by
- 128
- References
- 49
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 15 · 2020: 16 · 2019: 9 · 2018: 13 · 2017: 7 · 2016: 3
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- University of Pennsylvania
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R00HL103792)
- National Cancer Institute (R01CA190415)
- National Institute of Neurological Disorders and Stroke (R01NS094533)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, c-Met, endothelial plasticity, endothelial-to-mesenchymal transition, tumor vascularization, chemoresistance, temozolomide resistance, ETS1, MMP-14, vessel normalization, intratumoral hypoxia, cancer-associated fibroblasts, antivascular therapy
- MeSH terms
- Temozolomide, Animals, Cell Movement, Dacarbazine, Female, Glioblastoma, Humans, Male, Neovascularization, Pathologic, Cell Hypoxia, Mice, Knockout, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Endothelial Cells, Cell Proliferation, Proto-Oncogene Protein c-ets-1, Mice, Matrix Metalloproteinase 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
